Antiangiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.

Antiangiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.
Curr Med Chem. 2020 May 13;:
Authors: Cheng K, Liu CF, Rao GW
Abstract
Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of the drug development and chemical synthesis.
PMID: 32407259 [PubMed - as supplied by publisher]

Source: Current Medicinal Chemistry - May 12, 2020 Category: Chemistry Authors: Cheng K, Liu CF, Rao GW Tags: Curr Med Chem Source Type: research